Original Query: ALL
Previous Study | Return to List | Next Study

Ivermectin Versus Albendazole for Chronic Strongyloidiasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00765024
Recruitment Status : Completed
First Posted : October 2, 2008
Last Update Posted : September 7, 2017
Atlantic Laboratory Ltd
Information provided by (Responsible Party):
Mahidol University

Brief Summary:
A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Condition or disease Intervention/treatment Phase
Chronic Strongyloidiasis Drug: Ivermectin Drug: ivermectin Drug: Albendazole Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis
Actual Study Start Date : July 2008
Primary Completion Date : April 2010
Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Albendazole
Albendazole for 7 days
Drug: Albendazole
Albendazole 7 days
Experimental: ivermectin
ivermectin 200 mcg/kg single dose
Drug: Ivermectin
single dose of 200 mcg/kg
Other Name: stromectal
Experimental: ivermectin 2 doses
ivermectin 200 mcg/kg two doses in 2 weeks
Drug: ivermectin
two single dose of 200mcg/kg in 2 weeks
Other Name: stromectal

Primary Outcome Measures :
  1. cure rate [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. safety [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with positive strongyloides larva in the stool

Exclusion Criteria:

  • Pregnancy
  • Lactating women
  • Known allergy to any study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00765024

Siriraj Hospital
Bangkoknoi, Bangkok, Thailand, 10700
Sponsors and Collaborators
Mahidol University
Atlantic Laboratory Ltd
Principal Investigator: Yupin Suputtamongkol, MD Mahidol University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mahidol University Identifier: NCT00765024     History of Changes
Other Study ID Numbers: TM001-2008
First Posted: October 2, 2008    Key Record Dates
Last Update Posted: September 7, 2017
Last Verified: September 2017

Keywords provided by Mahidol University:
strongyloidiasis, ivermectin, albendazole

Additional relevant MeSH terms:
Rhabditida Infections
Secernentea Infections
Nematode Infections
Parasitic Diseases
Antiparasitic Agents
Anti-Infective Agents
Anticestodal Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents